DPP-4 inhibitors

Five advancements in diabetes treatment to watch
Five advancements in diabetes treatment to watchThe healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
A multifaceted approach to diabetes managementNew treatment options range from novel insulin therapies to GLP-1 agonists, DPP-4 inhibitors, SGLT-2 inhibitors, and more.
FDA warns of joint pain for DPP-4 diabetes drugs
FDA warns of joint pain for DPP-4 diabetes drugsFDA warned this week that several leading drugs for type 2 diabetes may cause severe and disabling joint pain. FDA said that sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain, and added a new Warning and Precaution about this risk to the labels of all dipeptidyl peptidase-4 (DPP-4) inhibitors.